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Abstract
TAS1R- and TAS2R-type taste receptors are expressed in the gustatory system, where they detect sweet- and bitter-tasting
stimuli, respectively. These receptors are also expressed in subsets of cells within the mammalian gastrointestinal tract,
where they mediate nutrient assimilation and endocrine responses. For example, sweeteners stimulate taste receptors on
the surface of gut enteroendocrine L cells to elicit an increase in intracellular Ca
2+ and secretion of the incretin hormone
glucagon-like peptide-1 (GLP-1), an important modulator of insulin biosynthesis and secretion. Because of the importance
of taste receptors in the regulation of food intake and the alimentary responses to chemostimuli, we hypothesized that
differences in taste receptor efficacy may impact glucose homeostasis. To address this issue, we initiated a candidate gene
study within the Amish Family Diabetes Study and assessed the association of taste receptor variants with indicators of
glucose dysregulation, including a diagnosis of type 2 diabetes mellitus and high levels of blood glucose and insulin during
an oral glucose tolerance test. We report that a TAS2R haplotype is associated with altered glucose and insulin homeostasis.
We also found that one SNP within this haplotype disrupts normal responses of a single receptor, TAS2R9, to its cognate
ligands ofloxacin, procainamide and pirenzapine. Together, these findings suggest that a functionally compromised TAS2R
receptor negatively impacts glucose homeostasis, providing an important link between alimentary chemosensation and
metabolic disease.
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Introduction
Taste strongly influences food preference and intake [1–3], and
taste receptor variants have been associated with differences in
taste perception [4–6], alcohol consumption [7–9] and tobacco use
[10]. TAS1R- and TAS2R-type taste receptors are expressed in
both the gustatory [11–13] and digestive [12,14] systems, where
they play important roles in taste sensation [11,13] and post-
ingestive nutrient responses [14–17], respectively. Bitter-tasting
compounds activate TAS2R receptors, while taste stimuli that
evoke perceptions of sweet or umami (e.g., the taste of glutamate)
are detected by receptors of the TAS1R family [11,12]. Variation
in sensitivity to some bitter-tasting molecules has a strong genetic
component in humans [12,18,19], and in certain cases has been
linked to polymorphisms in specific TAS2R receptor genes
[4,5,20]. There is little evidence for interindividual differences in
sweet taste sensitivity in humans, though a polymorphism that
decreases ligand affinity of mouse Tas1r3 also decreases sweet taste
sensitivity [12,21,22].
Both TAS1R and TAS2R taste receptors are expressed in the
gastrointestinal tract of rodents and humans [14–17,23–26].
TAS1Rs mediate nutrient assimilation and other physiological
responses to sweet-tasting stimuli [15–17], while TAS2Rs may be
important for responses to bitter-tasting stimuli [26]. For example,
the incretin hormone glucagon-like peptide-1 (GLP-1) is secreted
in a taste receptor-dependent manner by gut enteroendocrine L
cells in response to stimulation with natural and artificial
sweeteners [15]. GLP-1 impacts glucose homeostasis by regulating
glucose-stimulated insulin biosynthesis and secretion from pan-
creatic b-cells and by inhibiting glucagon secretion from
pancreatic a-cells [27].
Because of the important role of TAS1R and TAS2R taste
receptors in nutrient detection and response in the gustatory and
digestive systems, we hypothesized that allelic variations affecting
the function of individual TAS1Rs or TAS2Rs could significantly
impact glucose homeostasis. We initiated a candidate gene study
within the Amish Family Diabetes Study (AFDS) [28], followed by
functional characterization of candidate receptor variants, to
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3974identify specific sequence variants in TAS1R genes and/or TAS2R
genes that are associated with glucose homeostasis.
Results
Glucose dysregulation, including elevated plasma glucose,
increased hepatic gluconeogenesis, and decreased insulin mediated
glucose transport, is a hallmark of type 2 diabetes mellitus (T2DM)
[29]. We first asked whether any variants in taste receptor genes
are associated with T2DM in the Amish. We genotyped
haplotype-tagging, single nucleotide polymorphisms (SNPs) in or
around all TAS1R and TAS2R genes in all T2DM cases (n=145)
and a subset of controls (n=358) from the Amish Family Diabetes
Study (AFDS [28]; Tables 1–4). Only four SNPs, all on
chromosome 12, showed significant associations with T2DM
(Tables 1–3). Of these, the non-coding SNP rs2588350 showed
the greatest significance (P=0.0007; p_ACT value=0.025 after
correction for multiple comparisons). No SNPs on chromosomes 5
or 7 were associated with T2DM (Table 2). Surprisingly,
although both the TAS1R2 and TAS1R3 proteins are required
for normal glucose sensing in both the gustatory and gastrointes-
tinal systems (e.g., [16,17,30–32]), we observed no significant
associations with TAS1R haplotype-related SNPs (Table 3).
Indeed, all TAS1R3 SNPs were monomorphic in the Amish
(Table 3).
Next, we defined the extent of linkage disequilibrium (LD)
within the chromosome 12 TAS2R cluster. The cluster extends for
380 kb and contains three LD blocks (Figure 1). LD Block 1
contains rs2588350 along with two other SNPs with significant
T2DM associations (Table 1;r
2=0.50–0.83): rs619381, a
nonsynonymous coding SNP in TAS2R7 (C519T, encoding
Met304Ile; P=0.009; p_ACT=0.24) and rs3741845, another
nonsynonymous coding SNP in TAS2R9 (C560T, encoding
Ala187Val; P=0.005; p_ACT=0.15). Two haplotype-tagging
Table 1. Genotyping statistics for chromosome 12 TAS2R SNPs tested in the AFDS.
Chromosome,
Position (kb) SNP ID
Associated/
Nearest Gene
Call Rate
(%)
HWE
P Value
Major /
Minor
Allele MAF SNP Type
T2DM
Association
P Value
12, 10844 rs2588350 TAS2R7 97.3 0.679 C/T 0.07 noncoding 0.0007
12, 10846 rs619381 TAS2R7 94.3 0.419 C/T 0.07 M304I 0.009
12, 10853 rs3741845 TAS2R9 97.4 0.013 C/T 0.12 A187V 0.005
12, 10869 rs10845219
B TAS2R10 70.6 0.254 C/T 0.13 noncoding N/A
12, 10952 rs1015443
A TAS2R13 97.5 0.003 C/T 0.21 S259N N/A
12, 10983 rs7138535 TAS2R14 95.4 0.1 T/A 0.08 G38G 0.58
12, 11030 rs10772397
B TAS2R50 74.6 0.057 T/C 0.22 P259P N/A
12, 11030 rs1376251 TAS2R50 97.4 0.941 C/T 0.25 C203Y 0.99
12, 11032 rs6488334 TAS2R50 96.5 0.197 C/T 0.12 noncoding 0.04
12, 11039 rs10845278
B TAS2R49 71.8 0.149 T/C 0.50 noncoding N/A
12, 11042 rs7135018 TAS2R49 89.5 0.220 T/C 0.11 K79E 0.08
12, 11042 rs7301234 TAS2R49 91.3 0.601 G/A 0.28 noncoding 0.76
12, 11043 rs10772408 TAS2R49 94.3 0.576 T/C 0.40 noncoding 0.51
12, 11066 rs10772420 TAS2R48 95.6 0.122 A/G 0.34 C299R 0.60
12, 11066 rs1868769
A TAS2R48 93.4 2.04E-18 A/G 0.17 L140L N/A
12, 11067 rs4763235 TAS2R48 96.3 0.96 C/G 0.25 noncoding 0.95
12, 11073 rs11612527
B TAS2R44 65.2 0.656 T/A 0.11 noncoding N/A
12, 11075 rs10845293
A TAS2R44 95.3 2.50E-88 A/G 0.32 V227A N/A
12, 11105 rs2708381 TAS2R46 92.6 0.243 G/A 0.11 W250# 0.06
12, 11105 rs2708380 TAS2R46 97.1 0.107 T/A 0.39 L228M 0.69
12, n.d. rs3759245
A TAS2R45 93.4 0.001 T/C 0.12 C238R N/A
12, n.d. rs28581524 TAS2R45 91.3 0.160 C/G 0.24 H210Q 0.93
12, 11135 rs35720106
A TAS2R43 96.5 1.53E-44 C/G 0.24 T221T N/A
12, 11177 rs2599404 TAS2R47 97.1 0.629 C/A 0.36 L252F 0.77
12, 11230 rs1451772
A TAS2R55/42 95.7 5.27E-06 T/C 0.15 Y265C N/A
12, 11230 rs5020531 TAS2R55/42 96.2 0.025 C/T 0.25 S196F 0.84
Chromosome 12 TAS2R SNP found to be monomorphic in the AFDS: rs12578654.
AExcluded from further analysis due to failure of Hardy-Weinberg equilibrium (HWE) expectation (P,0.001).
BExcluded from further analysis due to call rate ,90%.
Bold indicates SNPs also reported in Table 2.
kb, kilobases.
n.d., not determined (the Celera genome sequence places TAS2R45 between TAS2R46 and TAS2R42).
# , stop codon.
MAF, minor allele frequency.
Covariates: age, sex, BMI, and with adjustments for family structure.
doi:10.1371/journal.pone.0003974.t001
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cluster (CSDA) show neither significant association with T2DM
(P=0.43 and P=0.24, respectively) nor LD (r
2#0.16) with the
TAS2R SNPs. These data suggest that a single LD block,
containing three TAS2R-tagging SNPs, is the principal taste
receptor-related locus for T2DM risk in the Amish.
To confirm that the T2DM association of these three SNPs
reflects an underlying dysregulation of glucose and insulin
homeostasis, we performed association analyses with glucose and
insulin traits obtained in 693 non-diabetic AFDS subjects who
had been given a standard 3-hour OGTT. The minor alleles of
all three SNPs were significantly associated with several
measures of glucose and insulin homeostasis (Table 5), including
glucose area-under-the-curve (AUC) and insulin response.
Insulin AUC was higher for individuals with the minor allele
of any of the three SNPs, but these differences were only
statistically significant for rs3741845 and rs2588350 (Table 5).
Estimates of insulin resistance based on homeostatic model
assessment were also significantly affected in subjects with the
rs3741845 T allele. Thus, the minor alleles of rs2588350,
rs619381 and rs3741845 display similar phenotypic associations.
As these three SNPs display significant LD (Figure 1), we
conclude that the minor alleles of these SNPs comprise a single
haplotype associated with dysregulated postprandial glucose
homeostasis.
Though any of the three SNPs within this glucose dysregulation
haplotype could potentially affect receptor expression or function,
and thus glucose and insulin homeostasis, the rs3741845 T allele is
a particularly attractive candidate risk allele: this SNP alters an
amino acid within a region of TAS2R9 that is predicted to
influence ligand binding and response of other GPCRs, including
TAS2Rs [33]. Therefore, we asked whether the Ala to Val change
alters the ligand response of TAS2R9. Since TAS2R9 was an
orphan receptor, we utilized a high-throughput screening strategy
to identify bitter-tasting stimuli that activate TAS2R9. Three of
the 64 bitter-tasting compounds screened (Supplemental data,
Table S1) activated TAS2R9 Ala187-expressing cells: the
fluoroquinolone antibiotic ofloxacin (Figure 2A and D), the
tricyclic gastric acid inhibitor pirenzapine (Figure 2B and E) and
the antiarrhythmic drug procainamide (Figure 2C and F). They
did so with an EC50 of 0.2, 1.8 and 2.8 mM, respectively. The
Val187 variant of TAS2R9 showed a dramatic loss of function,
with no responses to any of the bitter stimuli, even at high
concentrations (Figure 2D, E and F and data not shown). This
functional decrement is not due to differences in surface expression
(Figure 2G). Thus, the rs3741845 minor allele (T) causes a major
functional deficit in ligand response of TAS2R9.
Though the mechanism by which this taste receptor-associated
haplotype affects glucose and insulin homeostasis remains unclear,
these receptors could be involved in the modulation of GLP-1
Table 2. Genotyping Statistics for chromosome 5 and 7 TAS2R SNPs tested in the AFDS.
Chromosome,
Position (kb) SNP ID
Associated/
Nearest
Gene
Call Rate
(%)
HWE
P Value
Major /
Minor
Allele MAF SNP Type
T2DM
Association
P Value
5, 9681 rs41467 TAS2R1 94.9 0.291 G/T 0.47 noncoding 0.98
5, 9682 rs2234233 TAS2R1 94.5 0.809 C/T 0.24 R206W 0.91
7, 122420 rs1357949 TAS2R16 96.5 0.581 A/G 0.26 noncoding 0.50
7, 122421 rs6466849 TAS2R16 97.4 0.966 C/T 0.29 noncoding 0.97
7, 122422 rs860170 TAS2R16 94.9 0.089 A/G 0.38 H222R 0.36
7, 122423 rs978739 TAS2R16 97.7 0.014 A/G 0.35 noncoding 0.42
7, 141109 rs11763979 TAS2R3 98.4 0.227 G/T 0.27 noncoding 0.03
7, 141111 rs2270009
A TAS2R3 81.7 0.342 C/T 0.23 G269G N/A
7, 141111 rs2233998 TAS2R4 92.7 0.052 T/C 0.23 F7S 0.08
7, 141125 rs2234001 TAS2R4 97.0 0.073 G/C 0.23 V96L 0.08
7, 141137 rs2227264 TAS2R5 95.8 0.103 G/T 0.23 S26I 0.10
7, 141319 rs1726866 TAS2R38 97.0 0.430 T/C 0.24 V262A 0.07
7, 141320 rs713598
A TAS2R38 89.2 0.360 G/C 0.21 A49P N/A
7, 142592 rs4726600 TAS2R39 97.7 0.279 G/A 0.25 noncoding 0.33
7, 142630 rs10260248 TAS2R40 97.7 0.928 C/A 0.04 S187Y 0.29
7, 142631 rs534126 TAS2R40 98.0 0.622 C/T 0.38 noncoding 0.61
7, 142850 rs10241042
A TAS2R60 64.6 0.068 C/G 0.22 noncoding N/A
7, 142852 rs4595035 TAS2R60 97.7 0.616 C/T 0.35 R310R 0.86
7, 142885 rs1404634
A TAS2R41 72.9 0.150 G/A 0.43 noncoding N/A
7, 142885 rs1404635 TAS2R41 100 0.577 G/A 0.16 T63T 0.94
7, 142885 rs10278721 TAS2R41 97.7 0.653 C/T 0.16 P127L 0.88
Chromosome 7 TAS2R SNPs found to be monomorphic in the AFDS: rs13223346 and rs17464086.
AExcluded from further analysis due to call rate ,90%.
Bold indicates SNPs also reported in Table 1.
kb, kilobases.
MAF, minor allele frequency.
Covariates: age, sex, BMI, and with adjustments for family structure.
doi:10.1371/journal.pone.0003974.t002
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transcription-polymerase chain reaction (RT-PCR) to determine if
TAS2R9 is expressed in these cells. We amplified both TAS2R9
and TAS1R3 (a subunit of the sweet and umami taste receptors
previously reported to be expressed in enteroendocrine L cells
[15,23,25]) from cDNA obtained from NCI-H716 cells (a human
enteroendocrine L cell line; Figure 3A), from human cecum
(Figure 3A), and from human tongue (data not shown). We were
unable to amplify TAS2R7 from any of these cDNA pools
(Figure 3A and data not shown), though we could amplify a
product from human genomic DNA (data not shown). The
TAS2R9 products were amplified from cDNA and not genomic
DNA contaminants: PCR from control samples that were not
reverse transcribed gave no TAS2R9 product (data not shown),
and oligos that recognize coding sequences in exons 4 and 6 of
taste receptor TAS1R3 amplify a product lacking the two
intervening introns (Figure 3A). Independent clones of the
TAS2R9 product amplified from the NCI-H716 cells had either
an A or T at bp 560, indicating that this cell line is heterozygous
for this allele. Next, we tested whether a TAS2R9 ligand can
promote GLP-1 secretion from enteroendocrine L cells. Stimula-
tion of NCI-H716 cells with ofloxacin elicited a concentration-
dependent secretion of GLP-1 from this cell line (Figure 3B).
siRNA knockdown of the G protein a-gustducin (Figure 3C),
which mediates bitter taste responses in the tongue [34] and which
has been implicated in taste receptor-mediated GLP-1 secretion in
the gut [15], reduced ofloxacin-stimulated GLP-1 secretion
(Figure 3B). Together, these results are consistent with a role of
TAS2R9 in the regulation of nutrient-dependent GLP-1 secretion
from L cells.
Discussion
By combining human genetic approaches with high-through-
put receptor screening, we have identified an important link
between taste receptor function and the modulation of glucose
homeostasis. Our study provides genetic and biological validation
of an association between a TAS2R haplotype on human
chromosome 12 with the regulation of glucose and insulin levels.
The novel role of TAS2Rs in the maintenance of glucose
homeostasis should help elucidate the relative contributions of
taste receptor-mediated chemoreception in the gustatory and
digestive systems and suggests new lines of investigation for
ameliorating risk of metabolic disease and for developing novel
avenues for treatment.
Our conclusions are foremost based on the genetic association
of a TAS2R haplotype, including the TAS2R9 T560 allele, with
measures of glucose and insulin dysregulation in non-diabetic
Amish individuals (Table 5) and with increased incidence of
Table 3. Genotyping Statistics for TAS1R SNPs tested in the AFDS.
Chromosome,
Position (kb) SNP ID
Linked
Gene
Call
Rate
(%)
HWE
P Value
Major /
Minor
Allele MAF
1 SNP Type
T2DM
Association
P Value
1, 6546 RS4908563 TAS1R1 98.9 0.014 T/C 0.46 intronic 0.65
1, 6562 RS4908932 TAS1R1 93.5 0.194 G/T 0.17 noncoding 0.54
1, 19037 RS12036097 TAS1R2 97.2 0.112 G/A 0.46 noncoding 0.62
1, 19037 RS12034674
B TAS1R2 85.9 0.669 C/T 0.29 noncoding N/A
1, 19040 RS3935570 TAS1R2 96.0 0.227 G/T 0.17 intronic 0.77
1, 19042 RS12137730
A TAS1R2 90.8 0.085 A/C 0.46 intronic N/A
1, 19043 RS12567264 TAS1R2 93.2 0.132 T/A 0.29 Intronic 0.95
1, 19043 RS7534618 TAS1R2 97.6 0.148 T/G 0.29 intronic 0.86
1, 19044 RS12408808 TAS1R2 97.4 0.526 G/A 0.24 intronic 0.44
1, 19050 RS4076838 TAS1R2 93.8 0.525 T/C 0.29 intronic 0.30
1, 19052 RS4920564 TAS1R2 95.7 0.191 T/G 0.42 intronic 0.11
1, 19052 RS4920566 TAS1R2 96.6 0.378 A/G 0.25 intronic 0.97
1, 19054 RS28470550 TAS1R2 93.6 0.109 A/C 0.39 T294T 0.87
1, 19059 RS9701796 TAS1R2 96.9 0.866 G/C 0.11 C9S 0.29
TAS1R SNPs found to be monomorphic in the AFDS: rs6662276, rs12030791, rs12030797, rs307377, rs10864628, and rs28374389 (All TAS1R3 SNPs were monomorphic).
Aexcluded from further analysis due to genotype quality control issues.
BExcluded from further analysis due to call rate ,90%.
kb, kilobases.
MAF, minor allele frequency.
Covariates: age, sex, BMI, and with adjustments for family structure.
doi:10.1371/journal.pone.0003974.t003
Table 4. Age and BMI values, according to genotype, for
AFDS subjects in Table 1.
SNP Genotype Age (yrs) BMI (kg/m
2)
rs2588350 CC (n=600) 43.760.6 26.860.2
CT/TT (n=91) 45.661.4 27.460.5
rs619381 CC (n=633) 46.060.6 27.160.2
CT/TT (n=85) 47.661.6 27.360.5
rs3741845 CC (n=538) 43.460.6 26.860.2
CT/TT (n=155) 46.361.1 27.160.4
BMI, body-mass index.
Values are mean6std error.
There is a significant difference in age across genotype (P=0.02) between CC
and CT/TT individuals for rs3741845.
doi:10.1371/journal.pone.0003974.t004
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concordance of several related but independent phenotypic
measures (e.g., measures of glucose response during an OGTT,
measures of insulin response during an OGTT, and T2DM
diagnosis) with the same allele provides important internal
replication of the association. The few T2DM genome-wide
association studies (GWASs) that included rs619381 and
rs3741845 (but not rs2588350) [35–37] do not report significant
associations between T2DM and these SNPs. However, the
conservative cutoffs necessary for GWAS (,5610
27) would likely
exclude these associations from consideration in most studies.
Indeed, one heavily replicated T2DM gene, PPARG, would not
have met the criteria for a novel T2DM gene in at least one
GWAS [38]. The AFDS, though a relatively small study in a
homogeneous population, has exhibited sufficient power to
identify or replicate at least two T2DM risk alleles that are
replicated in other populations [39,40]. However, association
studies of rs3741845 in genetically heterogeneous populations may
be further complicated by population stratification, as the
frequency of the rs3741845 alleles varies greatly across human
populations (Supplementary data, Table S2). Further genetic and
mechanistic analyses will be needed to determine the extent to
which contributions of specific TAS2R variants to glucose
dysregulation are found in other populations.
We also provide important biological validation of the
association data: a physiological consequence of the TAS2R9
polymorphism (i.e., a loss of response to several ligands). The
rs3741845 SNP predicts an amino acid change in the second
extracellular loop or fifth transmembrane domain of TAS2R9, a
region suggested to form part of the ligand binding pocket and to
be important for receptor activation [33,41,42]. In contrast,
rs619381 affects an amino acid in the C-terminal domain of
TAS2R7, a region unlikely to directly impact ligand interactions,
and the rs2588350 SNP is a non-coding polymorphism. While any
of these SNPs could potentially impact TAS2R expression or
function, and therefore glucose and insulin homeostasis, we
reasoned that the TAS2R9 variant was the most likely to
significantly alter receptor function. The observation that
TAS2R9, but not TAS2R7, is expressed in human enteroendo-
crine cells (Figure 3) further supports a key role for TAS2R9. The
single amino acid change from Ala to Val at position 189 has a
profound effect on TAS2R9 function, abolishing responses to
three different ligands (Figure 2). No systematic structure-
function analyses have been performed for TAS2Rs, and studies
Figure 1. Haplotype structure of TAS2R SNPs on chromosome 12 in the AFDS. Pairwise LD (r
2) among 16 SNPs within the TAS2R cluster on
chromosome 12. The relative position of rs3759245 is based on a non-reference assembly (Celera). r
2 values 6100 are indicated within squares, and
with darker shades indicating higher r
2 values.
doi:10.1371/journal.pone.0003974.g001
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activation have been limited to TAS1Rs (e.g., [22,43,44]). Though
we cannot resolve whether the Ala to Val change specifically
impacts ligand binding, binding-induced conformational changes,
or effective G protein coupling, the inability of the Val187 variant
to respond to any of three different ligands provides compelling
evidence that this variant is incapable of transducing stimuli.
The observation that TAS2R9 is expressed in enteroendocrine
cells and that a TAS2R9 ligand can elicit GLP-1 secretion suggests
a possible mechanism, regulation of incretin response in the gut,
by which variation in taste receptor function could impact glucose
and insulin regulation. Gut TAS2Rs could be stimulated by a
number of compounds, including ingested toxins or bitter-tasting
peptides that result from the fermentation of proteins such as
casein [45]. Gut flora, which can vary dramatically between obese
and lean individuals [46,47], could also serve as a source of
TAS2R stimuli in normal or pathogenic states. Many TAS2Rs are
broadly tuned to multiple stimuli, and some bitter stimuli activate
more than one TAS2R [12,20,41,42,48–50]. The three TAS2R9
ligands identified in this study, ofloxacin, pirenzapine and
procainamide, are not natural ligands for this receptor, some of
which would be expected to activate TAS2R9 with a higher
efficacy. Even so, they do serve as effective tools to assay the
consequences of the Ala187Val mutation (Figure 2). Interestingly,
some fluoroquinolones, particularly gatifloxacin and levofloxacin
(the L-isomer of ofloxacin), have been associated with dysglycemia
in diabetic and non-diabetic patients [51]. TAS2R9 does not
respond to the three other fluoroquinolones we tested (gatifloxacin,
ciprofloxacin and enoxacin; Supplementary data, Table S1), but
it is intriguing to consider whether some bitter-tasting pharma-
ceuticals may affect glucose homeostasis, at least in part, through
actions on TAS2Rs.
However, we cannot rule out alternative physiological mecha-
nisms that link TAS2R function to the modulation of glucose
homeostasis. For example, taste receptors could affect glucose
homeostasis through a gustatory mechanism by altering the
perceived qualities of food and impacting food preference and
intake [6,30]. Indeed, taste receptor polymorphisms affect the
ability to recognize taste stimuli by altering the perceivedqualities of
food and impacting food preference and intake [1,6]. Intragastric
infusion of sweet- and bitter-tasting compounds also impacts taste
preference [52,53]. Therefore, blindness to particular bitter-tasting
compounds could lead to increased ingestion of toxins [3];
alternatively, hypersensitivity could result in avoidance of otherwise
beneficial foods (for example, individuals with the phenylthiocar-
bamide-sensitive version of TAS2R38 are more sensitive to the
bitterness of certain vegetables [6]). It is also unclear to what extent
the unique lifestyle and history of the Amish impacts the
contribution of TAS2R variants to manifestations of dysregulated
glucose and insulin homeostasis, including the development of
insulin resistance and T2DM. In any case, our studies reveal that
bitter taste receptors can influence glucose and insulin homeostasis.
The novel role of TAS2Rs in maintenance of glucose homeostasis
should help elucidate the relative contributions of taste receptor-
Figure 2. Differential activity of TAS2R9 alleles. (A–C) Calcium imaging assay of TAS2R9 Ala187 and Val187 variants responding to ofloxacin
(5 mM) (A), pirenzepine (20 mM) (B) and procainamide (10 mM) (C). (D–F) Dose-response functions of TAS2R9 Ala187 (black) and Val187 (red)
variants to ofloxacin (D), pirenzepine (E) and procainamide (F). Error bars are s.e.m. (G) Immunofluorescence staining of HEK293 cells transfected with
TAS2R9 Ala187, TAS2R9 Val187 or empty vector (mock).
doi:10.1371/journal.pone.0003974.g002
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new lines of investigation for ameliorating risk of metabolic disease
and for developing novel avenues for treatment.
Materials and Methods
Subjects
The University of Maryland School of Medicine’s Institutional
Review Board approved all studies. The Amish Family Diabetes
Study (AFDS) is an ongoing effort to identify genetic contributors to
obesity, diabetes, cardiovascular disease and related disorders
[28,39,54]. Detailed descriptions of the population (the Old Order
Amish of Lancaster County, Pennsylvania, USA), study design,
recruitment methods, phenotypic characterization, clinical charac-
teristics of the subjects and statistical methods have been published
previously [28]. Informed consent, including permission to contact
relatives, was obtained before participation [28]. In brief, probands
were defined as individuals with previously diagnosed diabetes (age
of diagnosis between 35 and 65 years). First- and second-degree
relatives of the probands were also recruited, as were first- and
second-degree relatives of any additional diabetic individuals
identified. Currently, the AFDS includes over 1300 subjects.
Participants in the AFDS, the Old Order Amish of Lancaster,
Pennsylvania, have a common lifestyle and socioeconomic status,
and possess detailed genealogical records dating to the period of
their early migration from Europe in the 1700’s [28].
Genotyping
We identified candidate haplotype tagging SNPs (r
2$0.8) from
the HapMap [55] and additional SNPs in coding and regulatory
regions from the Entrez SNP database [56] and from the literature
[4,8,57,58]. In total, 70 TAS1R- and TAS2R-associated SNPs were
genotyped in the AFDS. Forty-five of these SNPs were
polymorphic in the AFDS and passed quality control filters and
were subsequently analyzed (see below and Tables 1–3). All
SNPs were genotyped using the TaqMan platform (Applied
Biosystems) according to manufacturer’s protocols. SNPs found to
be monomorphic in the AFDS (n=9) were not analyzed further.
Genotypes were checked for Mendelian consistency; inconsisten-
cies, which were detected in ,0.5% of genotypes, were removed
from analysis. Genotype frequencies of all SNPs were tested for
consistency with Hardy–Weinberg expectations by the x
2 test.
Markers that showed extreme deviation from Hardy-Weinberg
Equilibrium in controls (P,0.001) were eliminated from further
analysis (n=7), as were SNPs with call rates ,90% (n=9).
Heterologous expression and functional assay
Receptor expression and functional assays were performed as
previously described [20,49]. We used FLIPR (Molecular Devices)
to screen the function of TAS2R9 and to establish dose-response
curves for the tested compounds (Supplementary data, Table S1).
We cloned the cDNAs encoding the TAS2R9 Ala
187 and Val
187
variants into a pEAK10-derived vector (Edge Biosystems,
Gaithersburg, MD). The vector was engineered to generate
translational fusion to the N-terminus of the rat somatostatin type
3 receptor (45 amino acids), and the C-terminus of the herpes
simplex virus (HSV) glycoprotein D epitope, as described [49].
Immunocytochemistry was performed using antiserum against
HSV glycoprotein D (Novagen, 1:10,000), as described [49],
except the secondary antibody was a FITC-conjugated donkey
antiserum against mouse IgG (Molecular Probes, 1:1,000).
Plasmids containing TAS2R9 cDNAs were transiently transfect-
ed into HEK293 cells stably expressing the chimeric G protein
subunit GÆ16gust44 [59] using TransIT-293 (Mirus Corporation),
according to the manufacturer’s protocol. Cells were plated into
384- well plates and after 24–30 hr loaded for 1 h with the
calcium-sensitive dye Fluo4-AM and stimulated with bitter
compounds. Calcium signals were recorded simultaneously from
each well after excitation at 488 nm. The obtained signals (F) were
normalized to the fluorescence of cells before stimulation (Fo) and
expressed as DF/F value: DF/F=(F2Fo) / Fo. Responses of four
wells containing cells expressing the same receptor and receiving
the same stimulus were averaged. Calculations were based on at
least three independent transfection experiments.
Reverse transcription PCR
Total RNA was isolated from human enteroendocrine NCI-
H716 cells with Trizol reagent, then reverse transcribed with
random hexamer probes. A reaction without reverse transcriptase
was included to control for genomic DNA contamination. Human
cecum cDNA was obtained from Biochain Institute (Hayward,
CA). TAS2R7 (GeneID: 50837) and TAS2R9 (GeneID: 50835)
gene specific primers recognized the single coding exons of each
gene. TAS1R3 (GeneID: 83756) gene specific primers were
directed against exons 4 and 6. All PCR products were verified
by sequencing.
GLP-1 assays
Human enteroendocrine NCI-H716 cells were maintained and
assayed for GLP-1 secretion as described by Jang et al. [15] in the
presence or absence of ofloxacin (Sigma Chemical) at 10, 50 or
100 mM in phosphate buffered saline (PBS), pH 7.2. Control
samples received PBS only. GLP-1 was measured by ELISA and
normalized to protein content. For siRNA knockdown experi-
Figure 3. TAS2R9 in enteroendocrine cells. (A) PCR amplicons for
TAS2R9 or TAS1R3 from NCI-H716 and human cecum cDNA. The size of
the TAS1R3 amplicon (434 bp) indicates no genomic DNA contamina-
tion (the genomic product would be 693 bp). TAS2R7 was not amplified
from either cDNA pool. (B) GLP-1 secretion from NCI H716 cells in
response to ofloxacin stimulation, normalized to the buffer only control,
in the absence (black) or presence (red) of an a-gustducin siRNA. The
specificity of the siRNA probe for a-gustducin in these cells was
previously reported [15]. Repeated measures ANOVA showed signifi-
cant effects of concentration (P,1610
29), siRNA treatment
(P=1.4610
25) and siRNA treatment X concentration (P=9 610
25).
Posthoc t-tests: * P,0.05; ** P,0.001. (C) Levels of a-gustducin
message in NCI H716 cells measured by quantitative real-time PCR in
the absence (black) or presence (red) of the a-gustducin siRNA and
normalized for a-gustducin levels in the absence of stimulus and siRNA.
Error bars: standard error.
doi:10.1371/journal.pone.0003974.g003
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into subconfluent NCI-H716 cells 48 hr prior to ofloxacin
stimulation and GLP-1 secretion analysis. Reduction of a-
gustducin message was verified by quantitative real time PCR.
The efficacy of the stimulation was significantly reduced after
knockdown of the G protein a-gustducin by RNA interference
(Figure S1B, C), indicating that ofloxacin-dependent GLP-1
secretion is mediated by a G protein-coupled receptor.
Statistical Analysis
Associations with SNP genotype and the various phenotypes
were performed using pedigree-based analysis by regressing the
effect of the marker genotype while accounting for residual familial
correlations among related individuals using age, sex, and body
mass index (BMI) as covariates (age and BMI are positively
correlated with T2DM in the AFDS). To account for the
relatedness among family members, we employed the measured
genotype approach, in which we estimated the likelihood of
specific genetic models given the pedigree structure. Parameter
estimates were obtained by maximum likelihood methods and the
significance of association was tested by likelihood ratio tests.
When discrete outcome traits were analyzed, a threshold model
was assumed. All analyses of the AFDS were carried out using the
Sequential Oligogenic Linkage Analysis Routines (SOLAR)
software program [60]. In the T2DM case/control analysis, a
recessive genetic model was assumed. When analyzing data from
non-diabetic AFDS subjects, a dominant model was assumed. To
control for an inflation in the type I error rate due to the number
of comparisons in our initial T2DM association analyses, we use
the PACT statistic [61], which attains the accuracy of permutation
or simulation-based correction through the adjustment of
correlated p-values. Unadjusted P values are reported in all tables.
Pairwise LD between the SNPs and haplotype block analysis
was computed using Haploview 4.0 [62]. Haplotype blocks were
defined by 95% confidence bounds on D’ [63]. Concentration-
response curves and EC50 values derived from the heterologous
expression and functional assays were calculated in SigmaPlot by
nonlinear regression.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0003974.s001 (0.05 MB
PDF)
Table S2
Found at: doi:10.1371/journal.pone.0003974.s002 (0.06 MB
PDF)
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Table 5. Associations with insulin and glucose metrics from OGTT in non-diabetic AFDS subjects.
Trait
rs2588350
(CC)
rs2588350
(CT/TT) P value
rs619381
(CC)
rs619381
(CT/TT) P value
rs3741845
(CC)
rs3741845
(CT/TT) P value
Glucose 30 min
(mmol/l)
8.4560.18
(n=636)
8.9560.19
(n=97)
0.006 8.4960.19
(n=614)
9.0360.20
(n=84)
0.005 8.4660.12
(n=568)
8.9660.15
(n=167)
0.0014
Glucose 60 min
(mmol/l)
8.2460.23
(n=632)
8.7660.25
(n=97)
0.029 8.2960.25
(n=610)
8.8960.27
(n=83)
0.016 8.2660.16
(n=564)
8.7260.19
(n=166)
0.0006
Glucose 90 min
(mmol/l)
6.5460.22
(n=634)
6.9960.24
(n=96)
0.045 6.5560.23
(n=612)
7.1560.25
(n=84)
0.01 6.5860.15
(n=568)
6.9060.18
(n=166)
0.012
Glucose 120 min
(mmol/l)
5.3160.18
(n=646)
5.7160.20
(n=97)
0.03 5.3160.19
(n=625)
5.7360.21
(n=83)
0.03 5.3560.12
(n=578)
5.4860.15
(n=167)
0.054
GAUC
(mmol/l)
19.960.2
(n=600)
21.360.4
(n=90)
0.043 18.8060.44
(n=580)
19.8960.47
(n=84)
0.01 19.860.2
(n=538)
21.060.3
(n=155)
0.036
Insulin Response
(pmol/l)
424.78646.63
(n=593)
548.74650.55
(n=91)
0.007 455.31646.42
(n=573)
533.14649.48
(n=79)
0.09 426.52632.09
(n=532)
512.67638.94
(n=155)
0.0086
Ln Insulin 30 min
(pmol/l)
5.6160.07
(n=630)
5.7160.07
(n=95)
0.12 5.6360.07
(n=608)
5.6560.07
(n=83)
0.76 5.6060.05
(n=562)
5.7160.05
(n=165)
0.017
Ln Insulin 60 min
(pmol/l)
5.7160.07
(n=625)
5.7760.07
(n=96)
0.54 5.7560.07
(n=603)
5.7660.07
(n=84)
0.86 5.7160.05
(n=557)
5.7960.06
(n=166)
0.1
Ln Insulin 90 min
(pmol/l)
5.3360.07
(n=627)
5.5160.07
(n=96)
0.012 5.3760.07
(n=605)
5.4960.07
(n=84)
0.07 5.3360.05
(n=561)
5.4760.06
(n=165)
0.0088
Ln Insulin 120 min
(pmol/l)
4.8460.08
(n=635)
5.0260.08
(n=95)
0.024 4.8760.08
(n=615)
4.9860.07
(n=83)
0.13 4.8560.05
(n=568)
4.9560.06
(n=165)
0.046
IAUC (mmol/l) 739.8618.0
(n=593)
889.8664.9
(n=91)
0.007 649.30650.21
(n=573)
731.07653.57
(n=79)
0.10 739.2619.4
(n=532)
858.2644.2
(n=155)
0.006
Ln HOMA 0.8560.05
(n=680)
0.9260.05
(n=102)
0.23 0.8760.04
(n=656)
0.9160.05
(n=90)
0.33 0.8560.03
(n=604)
0.9260.04
(n=176)
0.035
Values expressed as mean6standard error, with n=number of subjects.
Covariates: age, sex and BMI, and with adjustments for family structure.
GAUC: glucose area under the curve.
IAUC: insulin area under the curve.
Insulin Response=(Insulin AUC)23(Insulin at time 0).
Ln HOMA=natural log [(Insulin210 min)(fasting glucose)/22.5].
doi:10.1371/journal.pone.0003974.t005
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